Market Overview

Bristol-Myers, Pfizer Report Stroke, Systemic Embolism, Major Bleeding Uncommon in Eliquis Phase 3 ARISTOTLE Trial

Related BMY
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
The Stocks Already in Correction Mode (Fox Business)

Bristol-Myers
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced results of a post-hoc subanalysis
from the Phase III ARISTOTLE trial. Patients with nonvalvular atrial
fibrillation (NVAF) who are anticoagulated to reduce the risk of stroke
often undergo procedures for which temporary discontinuation of the
anticoagulant prior to and following the procedure is sometimes
warranted. This subanalysis describes the overall rates of key
post-procedural outcomes, such as stroke or systemic embolism and major
bleeding, among Eliquis and warfarin patients who underwent a
procedure during the ARISTOTLE trial, and examined any differences in
post-procedural events according to whether or not study drug was
interrupted. This subanalysis was presented today at the ESC

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Most Popular

Related Articles (BMY + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters